Afuco™ Anti-CD23 ADCC Therapeutic Antibody (Lumiliximab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant chimeric (primate/human) antibody expressed in CHO. Lumiliximab is a monoclonal antibody that targets CD23. It acts as an immunomodulator. The drug is a chimeric antibody from Macaca irus and Homo sapiens.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-760 |
| Pricing | Inquiry |
| Host | Primate |
| Target | CD23 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | IP, IF, FuncS, FC, Neut, ELISA |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |